These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 365182)

  • 41. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Antitumor immunoadjuvants of microbial origin: the limitations in the immune system and microbial structure].
    Cassone A
    Ann Ist Super Sanita; 1982; 18(3):497-500. PubMed ID: 6765082
    [No Abstract]   [Full Text] [Related]  

  • 43. Synthesis of N-acetyl-muramyl-L-alanyl-D-isoglutamine, an adjuvant of the immune response, and of some n-acetyl-muramyl-peptide analogs.
    Lefrancier P; Choay J; Derrien M; Lederman I
    Int J Pept Protein Res; 1977; 9(4):249-57. PubMed ID: 852928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues.
    Dinarello CA; Elin RJ; Chedid L; Wolff SM
    J Infect Dis; 1978 Dec; 138(6):760-7. PubMed ID: 368262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Absence of antibodies to muramyl dipeptide in patients with tuberculosis or leprosy.
    Bahr GM; Modabber FZ; Rook GA; Mehrotra ML; Stanford JL; Chedid L
    Clin Exp Immunol; 1982 Jan; 47(1):53-8. PubMed ID: 6807589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan.
    Chang YH; Pearson CM; Chedid L
    J Exp Med; 1981 Apr; 153(4):1021-6. PubMed ID: 6972989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brucella abortus vaccines: comparison of protection provided by immunopotentiated 45/20 bacterins and live strain 19 vaccine in guinea pigs.
    Woodard LF; Toone NM; Jasman RL
    Am J Vet Res; 1981 Nov; 42(11):1959-62. PubMed ID: 6802042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccination of experimental monkeys against Plasmodium falciparum: a possible safe adjuvant.
    Siddiqui WA; Taylor DW; Kan SC; Kramer K; Richmond-Crum SM; Kotani S; Shiba T; Kusumoto S
    Science; 1978 Sep; 201(4362):1237-9. PubMed ID: 99814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of thymus for N-acetyl muramyl-L-alanyl-D-isoglutamine-induced polyarthritis and granuloma formation in euthymic and athymic nude rats or in neonatally thymectomized rats.
    Kohashi O; Pearson CM; Tamaoki N; Tanaka A; Shimamura K; Ozawa A; Kotani S; Saito M; Hioki K
    Infect Immun; 1981 Feb; 31(2):758-66. PubMed ID: 7012019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Use of muramyl dipeptides in models of synthetic vaccines].
    Audibert F
    Boll Ist Sieroter Milan; 1985; 64(2):95-102. PubMed ID: 3896261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of antibodies directed against self and altered-self determinants by a synthetic adjuvant, muramyl dipeptide and some of its derivatives.
    Löwy I; Leclerc C; Chedid L
    Immunology; 1980 Mar; 39(3):441-50. PubMed ID: 6160092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic influences on the adjuvanticity of muramyl dipeptide in vivo.
    Staruch MJ; Wood DD
    J Immunol; 1982 Jan; 128(1):155-60. PubMed ID: 6976368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The immunomodulatory property of a novel synthetic compound adamantylamide dipeptide.
    Masek K; Seifert J; Flegel M; Krojidlo M; Kolínsky J
    Methods Find Exp Clin Pharmacol; 1984 Nov; 6(11):667-9. PubMed ID: 6530904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
    Allison AC; Byars NE
    J Immunol Methods; 1986 Dec; 95(2):157-68. PubMed ID: 3540125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opposite effects of the synthetic adjuvant N-acetyl-muramyl-L-alanyl-D-isoglutamine on the immune response in mice depending on experimental conditions.
    Souvannavong V; Adam A
    Eur J Immunol; 1980 Aug; 10(8):654-6. PubMed ID: 6995138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epithelioid granuloma formation by a synthetic bacterial cell wall component, muramyl dipeptide (MDP).
    Tanaka A; Emori K
    Am J Pathol; 1980 Mar; 98(3):733-48. PubMed ID: 6767407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine- induced arthritis: clinical and histologic studies in athymic nude and euthymic rats.
    Kohashi O; Aihara K; Ozawa A; Kotani S; Azuma I
    Lab Invest; 1982 Jul; 47(1):27-36. PubMed ID: 7087395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity.
    Arnon R; Sela M; Parant M; Chedid L
    Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6769-72. PubMed ID: 6935684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The adjuvant effect of synthetic glycopeptides on humoral immune response to thymus-dependent antigen].
    Kalina NG; Elkina SI; Moshiashvili IIa; Sergeev VV
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jun; (6):97-100. PubMed ID: 6613423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Study of immunomodulatory properties of N-acetylmuramyl-L-alanyl-D-isoglutamine and N-acetylglucosaminyl-(beta 1----4)-N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Dozmorov IM; Kuzin II; Lutsan NI; Lutsenko GV; Prokhorova AL; Sapozhnikov AM; Andronova TM; Ivanov VT
    Biomed Sci; 1991; 2(6):651-8. PubMed ID: 1841635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.